Search
for

    GlossaryHyperprolactinemia

    condition with abnormally high blood prolactin levels

    Hyperprolactinemia is a condition characterized by an abnormally high level of prolactin in the blood. Prolactin is a hormone produced by the pituitary gland that primarily stimulates breast milk production after childbirth. Elevated levels can lead to symptoms such as irregular menstrual cycles in women, erectile dysfunction in men, and can sometimes be associated with conditions like pituitary tumors or hypothyroidism.

    Related Terms

    Learn

    0 / 0 results
    — no results

    Research

    5 / 735 results

    Community Join

    5 / 6 results

      community does lowering your prolactin levels regrow hair?

      in Research/Science  9 upvotes 1 year ago
      The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.

      community how about progesterone cream?

      in Research/Science  22 upvotes 6 months ago
      Progesterone cream might help with hair loss by inhibiting DHT production and suppressing prolactin, which can increase DHT. Some dermatologists have used progesterone for hair loss treatment, and it has been effective, sometimes combined with minoxidil, finasteride, and hydrocortisone.

      community hmi115 is coming. Prepare yourselves for what's coming

      in Technology  110 upvotes 1 year ago
      The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  38 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.